Pimecrolimus, a topical calcineurin inhibitor for atopic dermatitis and other inflammatory skin diseases

Expert Review of Dermatology

Volumn 1, Issue 3, 2006, Pages 343-354

  Fowler, Joseph F ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

anti inflammatory; atopic dermatitis; efficacy; inflammatory skin diseases; pimecrolimus; safety; topical calcineurin inhibitor; treatment

Indexed keywords

EID: 36749016047     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/17469872.1.3.343     Document Type: Article

References (117)

1. Leung DY, Bieber T. Atopic dermatitis. Lancet 361 (9352), 151–160 (2003).
2. Eichenfield LF, Hanifin JM, Luger TA, Stevens SR, Pride HB. Consensus conference on pediatric atopic dermatitis. J. Am. Acad. Dermatol. 49 (6), 1088–1095 (2003).
3. Furue M, Terao H, Rikihisa W et al. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br. J. Dermatol. 148 (1), 128–133 (2003).
4. Mills CM, Marks R. Side effects of topical glucocorticoids. Curr. Prob. Dermatol. 21, 122–131 (1993).
5. Drake LA, Dinehart SM, Farmer ER et al. Guidelines of care for the use of topical glucocorticosteroids. American Academy of Dermatology. J. Am. Acad. Dermatol. 35 (4), 615–619 (1996).
6. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J. Aller. Clin. Immunol. 112 (6 Suppl.), S118 –S127 (2003).
7. Taylor B, Wadsworth J, Wadsworth M, Peckham C. Changes in the reported prevalence of childhood eczema since the 1939–45 war. Lancet 2 (8414), 1255–1257 (1984).
8. Larsen FS, Hanifin JM. Epidemiology of atopic dermatitis. Immunol. Aller. Clin. N. Am. 22 (1), 1–24 (2002).
9. Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J. Am. Acad. Dermatol. 30 (1), 35–39 (1994).
10. Paller AS, McAlister RO, Doyle JJ, Jackson A. Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin. Pediatr. (Phila.) 41 (5), 323–332 (2002).
11. Kemp AS. Atopic eczema: its social and financial costs. J. Paediatr. Child Health 35 (3), 229–231 (1999).
12. Bender BG, Leung SB, Leung DY. Actigraphy assessment of sleep disturbance in patients with atopic dermatitis: an objective life quality measure. J. Aller. Clin. Immunol. 111 (3), 598–602 (2003).
13. Dahl RE, Bernhisel-Broadbent J, Scanlon-Holdford S, Sampson HA, Lupo M. Sleep disturbances in children with atopic dermatitis. Arch. Pediatr. Adolesc. Med. 149 (8), 856–860 (1995).
14. Williams HC, Strachan DP. The natural history of childhood eczema: observations from the British 1958 birth cohort study. Br. J. Dermatol. 139 (5), 834–839 (1998).
15. Wuthrich B. Clinical aspects, epidemiology, and prognosis of atopic dermatitis. Ann. Aller. Asthma Immunol. 83 (5), 464–470 (1999).
16. Gustafsson D, Sjoberg O, Foucard T. Development of allergies and asthma in infants and young children with atopic dermatitis – a prospective follow-up to 7 years of age. Allergy 55 (3), 240–245 (2000).
17. Paller A. Might intervention in atopic eczema early in life halt the atopic march? Rationale for research with Elidel. Pediatr. Dermatol. 21 (3), 310 (2004).
18. Schafer-Korting M, Kleuser B, Ahmed M, Holtje HD, Korting HC. Glucocorticoids for human skin: new aspects of the mechanism of action. Skin Pharmacol. Physiol. 18 (3), 103–114 (2005).
19. Hughes J, Rustin M. Corticosteroids. Clin. Dermatol. 15 (5), 715–721 (1997).
20. Miller JA, Munro DD. Topical corticosteroids: clinical pharmacology and therapeutic use. Drugs 19 (2), 119–134 (1980).
21. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br. J. Dermatol. 142 (5), 931–936 (2000).
22. Bode HH. Dwarfism following long-term topical corticosteroid therapy. JAMA 244 (8), 813–814 (1980).
23. Turpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br. J. Dermatol. 115 (4), 475–484 (1986).
24. Aalto-Korte K, Turpeinen M. Pharmacokinetics of topical hydrocortisone at plasma level after applications once or twice daily in patients with widespread dermatitis. Br. J. Dermatol. 133 (2), 259–263 (1995).
25. du Vivier A, Stoughton RB. Tachyphylaxis to the action of topically applied corticosteroids. Arch. Dermatol. 111 (5), 581–583 (1975).
26. Capella GL, Casa-Alberighi OD, Finzi AF. Therapeutic concepts in clinical dermatology: cyclosporine A in immunomediated and other dermatoses. Int. J. Dermatol. 40 (9), 551–561 (2001).
27. Billich A, Aschauer H, Aszodi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int. J. Pharm. 269 (1), 29–35 (2004).
28. Kalthoff FS, Chung J, Musser P, Stuetz A. Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin. Exp. Immunol. 133 (3), 350–359 (2003).
29. Grassberger M, Baumruker T, Enz A et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br. J. Dermatol. 141 (2), 264–273 (1999).
30. Meingassner JG, Stutz A. Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases? J. Invest. Dermatol. 98 (6), 851–855 (1992).
31. Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stutz A. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br. J. Dermatol. 137 (4), 568–576 (1997).
32. Kalthoff FS, Chung J, Stuetz A. Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells. Clin. Exp. Immunol. 130 (1), 85–92 (2002).
33. Hoetzenecker W, Ecker R, Kopp T, Stuetz A, Stingl G, Elbe-Burger A. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. J. Aller. Clin. Immunol. 115 (6), 1276–1283 (2005).
34. Hultsch T, Muller KD, Meingassner JG, Grassberger M, Schopf RE, Knop J. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch. Dermatol. Res. 290 (9), 501–507 (1998).
35. Zuberbier T, Chong SU, Grunow K, Guhl S, Welker P, Grassberger M et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J. Aller. Clin. Immunol. 108 (2), 275–280 (2001).
36. Meingassner JG, Kowalsky E, Schwendinger H, Elbe-Burger A, Stutz A. Pimecrolimus does not affect Langerhans cells in murine epidermis. Br. J. Dermatol. 149 (4), 853–857 (2003).
37. Hoetzenecker W, Meingassner JG, Ecker R, Stingl G, Stuetz A, Elbe-Burger A. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J. Invest. Dermatol. 122 (3), 673–684 (2004).
38. Vicari AP, Caux C, Trinchieri G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol. 12 (1), 33–42 (2002).
39. Rowe J, Macaubas C, Monger TM et al. Antigen-specific responses to diphtheria–tetanus–acellular pertussis vaccine in human infants are initially Th2 polarized. Infect. Immun. 68 (7), 3873–3877 (2000).
40. Novak N, Bieber T, Leung DY. Immune mechanisms leading to atopic dermatitis. J. Aller. Clin. Immunol. 112 (6 Suppl.), S128 –S139 (2003).
41. Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 211 (2), 174–187 (2005).
42. Meingassner JG, Fahrngruber H, Bavandi A. Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporine A. J. Invest. Dermatol. 121 (1), 77–80 (2003).
43. Harper J, Green A, Scott G et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br. J. Dermatol. 144 (4), 781–787 (2001).
44. ®), SDZASM981) in patients with atopic dermatitis. Dermatology 204 (1), 63–68 (2002).
45. Allen BR, Lakhanpaul M, Morris A et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch. Dis. Child. 88 (11), 969–973 (2003).
46. Thaci D, Steinmeyer K, Ebelin ME, Scott G, Kaufmann R. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study. Dermatology 207 (1), 37–42 (2003).
47. Ling M, Gottlieb A, Pariser D et al. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis. J. Dermatol. Treat. 16 (3), 142–148 (2005).
48. Staab D, Pariser D, Gottlieb AB et al. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis – a multicenter, 3-week, open-label study. Pediatr. Dermatol. 22 (5), 465–471 (2005).
49. Paul C, Cork M, Rossi AB, Papp KA, Barbier N, de Prost Y. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics 117 (1), E118 –E128 (2006).
50. Rappersberger K, Komar M, Ebelin ME et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J. Invest. Dermatol. 119 (4), 876–887 (2002).
51. Wolff K, Fleming C, Hanifin J et al. Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. Br. J. Dermatol. 152 (6), 1296–1303 (2005).
52. Gottlieb AB, Griffiths CE, Ho VC et al. Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. Br. J. Dermatol. 152 (6), 1219–1227 (2005).
53. Eichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J. Am. Acad. Dermatol. 46 (4), 495–504 (2002).
54. Ho VC, Gupta A, Kaufmann R et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J. Pediatr. 142 (2), 155–162 (2003).
55. Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 205 (3), 271–277 (2002).
56. Meurer M, Fartasch M, Albrecht G et al. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 208 (4), 365–372 (2004).
57. Wahn U, Bos JD, Goodfield M et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 110 (1 Pt 1), E2 (2002).
58. Kapp A, Papp K, Bingham A et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J. Aller. Clin. Immunol. 110 (2), 277–284 (2002).
59. Papp KA, Werfel T, Folster-Holst R et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J. Am. Acad. Dermatol. 52 (2), 240–246 (2005).
60. Papp K, Staab D, Harper J et al. Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis. Int. J. Dermatol. 43 (12), 978–983 (2004).
61. Boguniewicz M, Eichenfield LF, Hultsch T. Current management of atopic dermatitis and interruption of the atopic march. J. Aller. Clin. Immunol. 112 (6 Suppl.), S140 –S150 (2003).
62. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N. Engl. J. Med. 341 (24), 1817–1828 (1999).
63. Crutchfield CE, III. Pimecrolimus: a new treatment for seborrheic dermatitis. Cutis 70 (4), 207–208 (2002).
64. Brownell I, Quan LT, Hsu S. Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol. Online J. 9 (3), 13 (2003).
65. Rallis E, Nasiopoulou A, Kouskoukis C, Koumantaki E. Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk. Drugs Exp. Clin. Res. 30 (5–6), 191–195 (2004).
66. Warshaw E, Wohlhuter J, Drake D et al. Randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J. Invest. Dermatol. 125 (1), A3 (2005).
67. Rigopoulos D, Ioannides D, Kalogeromitros D, Gregoriou S, Katsambas A. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br. J. Dermatol. 151 (5), 1071–1075 (2004).
68. Mrowietz U, Graeber M, Brautigam M et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br. J. Dermatol. 139 (6), 992–996 (1998).
69. Gribetz C, Ling M, Lebwohl M et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J. Am. Acad. Dermatol. 51 (5), 731–738 (2004).
70. Belsito DV, Fowler JF Jr, Marks JG Jr et al. Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis 73 (1), 31–38 (2004).
71. Mayoral FA, Gonzalez C, Shah NS, Arciniegas C. Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology 207 (3), 322–323 (2003).
72. Kreuter A, Gambichler T, Breuckmann F et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J. Am. Acad. Dermatol. 51 (3), 407–410 (2004).
73. Zabawski E. Treatment of cutaneous lupus with Elidel. Dermatol. Online J. 8 (2), 25 (2002).
74. Goldstein AT, Marinoff SC, Christopher K. Pimecrolimus for the treatment of vulvar lichen sclerosus in a premenarchal girl. J. Pediatr. Adolesc. Gynecol. 17 (1), 35–37 (2004).
75. Larangeira de Almeida H Jr. Successful treatment of chronic actinic dermatitis with topical pimecrolimus. Int. J. Dermatol. 44 (4), 343–344 (2005).
76. Ziemer M, Gruhn B, Thiele JJ, Elsner P. Treatment of extensive chronic cutaneous graft-versus-host disease in an infant with topical pimecrolimus. J. Am. Acad. Dermatol. 50 (6), 946–948 (2004).
77. Schmook T, Kraft J, Benninghoff B et al. Treatment of cutaneous chronic graft-versus-host disease with topical pimecrolimus. Bone Marrow Transplant. 36 (1), 87–88 (2005).
78. Esquivel-Pedraza L, Fernandez-Cuevas L, Ortiz-Pedroza G, Reyes-Gutierrez E, Orozco-Topete R. Treatment of oral lichen planus with topical pimecrolimus 1% cream. Br. J. Dermatol. 150 (4), 771–773 (2004).
79. Dissemond J, Schroter S, Franckson T, Herbig S, Goos M. Pimecrolimus in an adhesive ointment as a new treatment option for oral lichen planus. Br. J. Dermatol. 150 (4), 782–784 (2004).
80. Swift JC, Rees TD, Plemons JM, Hallmon WW, Wright JC. The effectiveness of 1% pimecrolimus cream in the treatment of oral erosive lichen planus. J. Periodontol. 76 (4), 627–635 (2005).
81. Oji V, Beljan G, Beier K, Traupe H, Luger TA. Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. Br. J. Dermatol. 153 (5), 1067–1068 (2005).
82. Amichai B. Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream. J. Eur. Acad. Dermatol. Venereol. 18 (6), 742–743 (2004).
83. Black RJ. Vulval eczema associated with propolis sensitization from topical therapies treated successfully with pimecrolimus cream. Clin. Exp. Dermatol. 30 (1), 91–92 (2005).
84. Bohm M, Bonsmann G, Luger TA. Resolution of lichen aureus in a 10-year-old child after topical pimecrolimus. Br. J. Dermatol. 151 (2), 519–520 (2004).
85. Chu CY. The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. Br. J. Dermatol. 152 (2), 396–399 (2005).
86. Lim SJ, Love EW. Steroid-free pimecrolimus (Elidel) for monotherapy of lichen planus. J. Drugs Dermatol. 3 (5), 563–564 (2004).
87. Sulit DJ, Harford R, O’Neill JT. Discrete papular form of lichen myxedematosus: a case report and review of the literature. Cutis 75 (2), 105–112 (2005).
88. Tzung TY, Wu JC. Topical calcineurin inhibitors in treating Jessner’s lymphocytic infiltration of the skin: report of a case. Br. J. Dermatol. 152 (2), 383–384 (2005).
89. Rigopoulos D, Prantsidis A, Christofidou E, Ioannides D, Gregoriou S, Katsambas A. Pimecrolimus 1% cream in the treatment of disseminated granuloma annulare. Br. J. Dermatol. 152 (6), 1364–1365 (2005).
90. Arican O, Ciralik H, Sasmaz S. Unsuccessful treatment of extragenital lichen sclerosus with topical 1% pimecrolimus cream. J. Dermatol. 31 (12), 1014–1017 (2004).
91. Bos JD. Topical tacrolimus and pimecrolimus are not associated with skin atrophy. Br. J. Dermatol. 146 (2), 342 (2002).
92. Queille-Roussel C, Paul C, Duteil L et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br. J. Dermatol. 144 (3), 507–513 (2001).
93. ®, Novartis Pharmaceuticals, East Hanover, NJ, USA (2006).
94. Kempers S, Boguniewicz M, Carter E, Jarratt M, Pariser D, Stewart D et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J. Am. Acad. Dermatol. 51 (4), 515–525 (2004).
95. Luger TA, Lahfa M, Folster-Holst R, Gulliver WP, Allen R, Molloy S et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J. Dermatol. Treat. 15 (3), 169–178 (2004).
96. Bonifazi E, Garofalo L, Pisani V, Meneghini CL. Role of some infectious agents in atopic dermatitis. Acta Derm. Venereol. Suppl. (Stockh.) 114, 98–100 (1985).
97. David TJ, Longson M. Herpes simplex infections in atopic eczema. Arch. Dis. Child. 60 (4), 338–343 (1985).
98. Lubbe J, Stucky L, Saurat JH. Rosaceiform dermatitis with follicular Demodex after treatment of facial atopic dermatitis with 1% pimecrolimus cream. Dermatology 207 (2), 205–207 (2003).
99. Segura S, Romero D, Carrera C, Iranzo P, Estrach T. Eczema herpeticum during treatment of atopic dermatitis with 1% pimecrolimus cream. Acta Derm. Venereol. 85 (6), 524–525 (2005).
100. Tran C, Antille C, Sorg O, Saurat HJ, Lubbe J. Effects of topical calcineurin inhibitors (tacrolimus, pimecrolimus) on UVB-induced DNA-damage in mouse and human skin in vivo. Poster presented at: Annual meeting of Swiss Academy of Dermatology and venereology Basel, Switzerland (2003).
101. Doelker I, Tran C, Sorg O, Surat J-H, Lubbe J. Kinetics of cyclobutane dipyrimidine dimer production and clearance in the skin of UV-irradiated skin pretreated with topical calcineurin inhibitors of corticosteroids in normal and atopic patients. Eur. Acad. Dermatol. Venereol. 19 (Suppl. 2), 1–45 (2006).
102. Bieber T, Cork M, Ellis C et al. Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 211 (2), 77–78 (2005).
103. Ring J, Barker J, Behrendt H et al. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors. J. Eur. Acad. Dermatol. Venereol. 19 (6), 663–671 (2005).
104. Fonacier L, Spergel J, Charlesworth EN, Weldon D, Beltrani V, Bernhisel-Broadbent J et al. Report of the topical calcineurin inhibitor task force of the american college of allergy, asthma and immunology and the american academy of allergy, asthma and immunology. J. Aller. Clin. Immunol. 115 (6), 1249–1253 (2005).
105. Papp KA, Breuer K, Meurer M, Ortonne JP, Potter PC, de Prost Y et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J. Am. Acad. Dermatol. 52 (2), 247–253 (2005).
106. Asthma and Allergy Foundation of America. Asthma and Allergy Foundation of America’s April 5, 2005, letter to the FDA. Asthma and Allergy Foundation of America, Chicago, IL, USA (2005).
107. Bindslev-Jensen C, Zuberbier T, Eigenmann P, Wahn I. Finding a balance on precaution. EAACI Newsletter 6, 14 (2005).
108. JDGG (German Dermatology Society). Statement issued by the German Dermatology Society (DDG) in response to the US FDA’s decision concerning the use of pimecrolimus cream and tacrolimus ointment for the treatment of atopic dermatitis (eczema). JDDG. 3 (6), 415 (2005).
109. Girolomoni G, Gelmetti C, Vierucci A. The safety profile of topical pimecrolimus in the treatment of atopic dermatitis. G. Ital. Dermatol. Venereol. 36, 126–130 (2005).
110. Inflammatory Skin Disease Institute. FDA announces it is adding a “black box warning label on the eczema medications pimecrolimus (elidel) and tacrolimus (protopic), Portland, OR, USA (2006).
111. Kaufmann R, Folster-Holst R, Hoger P et al. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. J. Aller. Clin. Immunol. 114 (5), 1183–1188 (2004).
112. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981) – preclinical pharmacologic profile and skin selectivity. Semin Cutan. Med. Surg. 20 (4), 233–241 (2001).
113. Presidential statement on topical calcineurin inhibitors www.eadv.org.
114. ® for the treatment of atopic dermatitis (eczema). www.oegdv.at/dl/Blackbox_Warnung_1.
115. AEDV (Spanish Academy of Dermatology and Vereology). Spanish Academy of Dermatology and Venereology. www.aedv.es/contenido/AEDV_Eczema.
116. Cockerell CJ. American Academy of Dermatology. President’s message: elidel and protopic alert. Academy disappointed with restrictive new labeling for eczema medication, working to enhance dialogue with FDA www.aad.org
117. The National Eczema Association’s statement concerning the use of protopic and elidel (topical calcineurin inhibitors). www.isdionline.org